Gland Pharma Ltd Stock Analysis

BSE: 543245 | NSE: GLAND | Pharmaceuticals & Drugs | Large Cap

BSE Share Price Jan 24, 12:23
3365.85 -203.85 (-5.71%)

DeciZen - Make an Informed Decision on Gland Pharma

Overall Rating

1. Quality

2. Valuation

Fair
P/E P/S EV/EBITDA

3. Price Trend

Semi Strong

FAQ's

1. Is Gland Pharma Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Gland Pharma Ltd is a good quality company.

2. Is Gland Pharma Ltd undervalued or overvalued?

The key valuation ratios of Gland Pharma Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Gland Pharma Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Gland Pharma Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Gland Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gland Pharma Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide
Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
ROCE % 0%0%0%0%0%0%0%0%19.6%20.3%-
Value Creation Index NANANANANANANANA0.80.8-

Growth Parameters

Growth Parameters Colour Code Guide
Sales 000000002,6333,4634,185
YoY Gr. Rt. %-NANANANANANANANA31.5%-
Adj EPS 000000004659.272.2
YoY Gr. Rt. %-NANANANANANANANA28.8%-
BVPS (₹) 00000000234.3359.3418.1
Adj Net Profit 000000007129691,186
Cash Flow from Ops. 00000000701605-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide
9 Years 5 Years 3 Years 1 Years
Sales NANANA31.5%
Adj EPS NANANA28.8%
BVPS 00053.4
Share Price - - - 47.4%

Key Financial Parameters

Performance Ratio Colour Code Guide
Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity % 0000000019.520.318.6
Op. Profit Mgn % 0000000036.337.635.6
Net Profit Mgn % 00000000272828.3
Debt to Equity 0000000000-
Working Cap Days 0000000002000
Cash Conv. Cycle 0000000001220

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 18.60%

Sales growth is good in last 4 quarters at 30.98%

Sales growth has been subdued in last 3 years 0.00%

Net Profit has been subdued in last 3 years 0.00%

Latest Financials - Gland Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 72.2 72.2
TTM Sales (₹ Cr.) 4,185 4,185
BVPS (₹.) 418.1 418.1
Reserves (₹ Cr.) 6,853 6,852
P/BV 8.54 8.52
PE 49.43 49.31
From the Market
52 Week Low / High (₹) 2051.00 / 4350.00
All Time Low / High (₹) 1701.00 / 4350.00
Market Cap (₹ Cr.) 58,651
Equity (₹ Cr.) 16.4
Face Value (₹) 1
Industry PE 39.1

Management X-Ray of Gland Pharma :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Analyst's Notes

News

About Gland Pharma Ltd

The company was incorporated as Gland Pharma Private Limited, a private limited company, at Hyderabad under the Companies Act, 1956 on March 20, 1978 and was granted the certificate of incorporation by the Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of the company was changed to Gland Pharma Limited pursuant to a special resolution passed by the shareholders of the Company on December 5, 1994, and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act, 1956.

The company is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019. It sells its products primarily under a business to business (B2B) model in many countries including the United States, Europe, Canada, Australia, India and the Rest of the world. It has a consistent compliance track record with a range of regulatory regimes across these markets. It also has an extensive track record in complex injectables development, manufacturing and marketing and a close understanding of the related sophisticated scientific, technical and regulatory processes. It was established in Hyderabad, India in 1978 and has expanded from liquid parenterals to cover other elements of the injectables value chain, including contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a range of delivery systems. It has a professional management team and one of its Promoters, Shanghai Fosun Pharma, is a global pharmaceutical major.

Business area of company

The company is focused on meeting diverse injectables needs with a stable supply of affordable and high quality products. It has established a portfolio of injectable products across various therapeutic areas and delivery systems. It is present in sterile injectables, oncology and ophthalmics, and focus on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings. Its delivery systems include liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops. It is expanding its development and manufacturing capabilities in complex injectables such as peptides, long-acting injectables, suspensions and hormonal products as well as new delivery systems such as pens and cartridges.

Awards, accreditations and recognitions:

2014:

  • Awarded the ‘Outstanding Exports Performance Award’ under the Regional (America and Oceania) category by Pharmaceuticals Export Promotion Council of India.
  • Received the BS OHSAS 18001:2007 certifying the occupational health and safety management system of our manufacturing facility at Dundigal.
  • Received ISO 14001:2015 certifying the environmental management system of company’s manufacturing facility at Dundigal.
  • Received ISO 9001:2015 certifying the quality management system of manufacturing facility at Dundigal.

2016:

  • Awarded the ‘Top Exporter/Importer’ by the Hyderabad Customs Commissionerate, Customs and Central Excise, Government of India.

2017:

  • Awarded the ‘Excellence in Export Performance’ at the Federation of Telangana and Andhra Pradesh Chambers of Commerce and Industry instituted by Surana Group of Industries, Secunderabad.
  • Awarded the ‘Outstanding Export Performance Award’ under Formulations Fast Growing -1 category by Pharmaceuticals Export Promotion Council of India.

2018:

  • Awarded the ‘Top Exporter’ by the Hyderabad Customs, Customs and Central Excise, Government of India.
  • Awarded the ‘Outstanding Export Performance Award’ under Formulations Silver Star category by Pharmaceuticals Export Promotion Council of India.

2019:

  • Awarded the ‘Best Exporter’ by the Hyderabad Customs.
  • Awarded the ‘Express Pharma Excellence Awards 2019’ under the turnover base Rs 500-2000 crore category organized by the Express Pharma and Optel Group.
  • Awarded the ‘Telangana Best Employer Brand Award’ at the 14th Employer Branding Awards organised by the Employer Branding Institute, India.

Major events and milestones

  • 1978: Incorporation of the Company by P.V.N. Raju.
  • 2000: Set up the in-house R&D facility at Dundigal, Hyderabad.
  • 2003: Received USFDA approval for the manufacturing facility at Dundigal.
  • 2004 -2 005: Launch of Enoxaparin Sodium Injection (Cutenox) in India and Rest of the world markets.
  • 2007: Capital infusion of approximately Rs 1,000 million into the Company pursuant to private equity investment aggregating to approximately Rs 1,200 million with EILSF Co-Invest I LLC.
  • 2010: Launched Heparin Sodium Injection in the US.
  • 2012: Received the ‘Certificate of GMP Compliance of a Manufacturer’ from BGV Hamburg (Germany) for manufacturing facility at Dundigal.
  • 2014: Obtained USFDA approval for small volume parenteral manufacturing facility at Visakhapatnam.
  • 2014: Commissioned the Pashamylaram Unit-II manufacturing facility.
  • 2014: Received the ‘Certificate of GMP Compliance of a Manufacturer’ from MHRA (UK) for manufacturing facility at Dundigal.
  • 2014: Capital infusion of $100 million into the Company pursuant to private equity investment aggregating to approximately $ 200 million with KKR Floorline Investment.
  • 2016: Obtained USFDA approval for facilities at Jawaharlal Nehru Pharma City, Visakhapatnam.
  • 2016: Obtained USFDA approval for manufacturing facility at Pashamylaram.
  • 2016: Obtained USFDA approval for facility at the Visakhapatnam Special Economic Zone.
  • 2017: Fosun Singapore acquired 74% stake in the Company.
  • 2018: Received ANDA approval for Enoxaparin Sodium Injection USP for the US market.
  • 2018: Received ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%, our first Ophthalmic product approval.
  • 2019: Filed Dexrazoxane for Injection, company’s first filing with the National Medical Products Administration, China, and received clinical waiver.
Read More Read Less